RNA-based drugs: from RNA interference to short interfering RNAs.
RNA interference consists of a sequence specific post-transcriptional gene silencing phenomenon triggered by a double strand RNA molecule homologous to the silenced gene. The dsRNA is cleaved by DICER enzyme in small dsRNA pieces, named short interfering RNAs (siRNAs). These fragments are thereafter associated to RISC complex where the cleavage of target RNA occurs. The observation that siRNAs can trigger the RNA interference mechanism in mammalian cells represents a fundamental discovery that discloses new horizons in genetic researches in that theoretically each gene can be silenced. The relative simplicity by which active short interfering RNAs can be designed and synthesized explains their widespread use in basic and applied researches, even if appropriate controls that exclude off-target effects are strictly required. The findings that siRNAs are active even when expressed in viral vectors open the possibility that they can be very soon used for gene therapy of several human diseases.
Laboratorio di Terapia Genica e Molecolare, Istituto di Fisiologia Clinica, Area della Ricerca del CNR, Pisa, Italy.
L
L
Poliseno
A
A
Mercatanti
L
L
Citti
G
G
Rainaldi
D000818:Animals; D015195:Drug Design; D020868:Gene Silencing; D018390:Gene Targeting / Q000379:methods*; D018014:Gene Transfer Techniques; D005818:Genetic Engineering / Q000379:methods; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy*; D034741:RNA, Small Interfering / Q000235:genetics* / Q000627:therapeutic use*; D034743:RNA-Induced Silencing Complex / Q000235:genetics
D034741:RNA, Small Interfering; D034743:RNA-Induced Silencing Complex